21:05 , Nov 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Hepatitis C virus (HCV); HIV/AIDS; coronavirus; viral infection Cell culture and in vitro studies identified phenylpyrrolidine-based inhibitors of CYPA , CYPB and CYPD that could help treat HCV, HIV/AIDS, coronavirus and other viral infections....
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Infusible Platelet Membrane data

Cypress Bioscience Inc. (CYPB), San Diego, Calif.   Product: Infusible Platelet Membrane (IPM)   Indication: Active bleeding   CYPB announced results of a Phase II trial in patients with low platelet counts during active bleeding....
07:00 , May 10, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Aptamer-based assay against secreted proteins for the identification of new cancer biomarkers An aptamer-based assay of secreted proteins may help identify new cancer biomarkers....
08:00 , Jan 10, 2011 |  BC Week In Review  |  Company News

Cypress Bioscience, Royalty Pharma, Ramius LLC deal

Ramius and Royalty completed their previously announced tender offer for Cypress, acquiring 28.7 million shares (73.6%) at $6.50 per share in cash, or about $186.6 million, to raise the companies' holdings in Cypress to 83.5%....
08:00 , Jan 10, 2011 |  BioCentury  |  Finance

Buyside View XIX: Commercial Risk

Michael Flanagan Senior Writer  BioCentury's 19th Annual Buyside View finds money managers entering 2011 cautiously optimistic about biotech's prospects, particularly as some of the high-profile compounds have already reported some data, lowering risk. Amidst the...
08:00 , Jan 3, 2011 |  BC Week In Review  |  Company News

Cypress Bioscience, Royalty Pharma, Ramius LLC deal

Ramius and Royalty extended to midnight on Jan. 5, 2011, from Dec. 30, 2010, the deadline for their tender offer to acquire the 90.1% of Cypress that Ramius does not already own for $6.50 per...
08:00 , Dec 20, 2010 |  BC Week In Review  |  Company News

Cypress Bioscience, Royalty Pharma, Ramius LLC deal

Cypress' agreed to a $6.50 per share cash offer by Ramius and Royalty to acquire the 90.1% of Cypress that Ramius does not already own. Ramius said on Dec. 14 that Cypress rejected a $6...
08:00 , Dec 20, 2010 |  BioCentury  |  Analyst Picks & Changes

Analyst Picks & Changes

Analyst Picks & Changes Wk 12/17 Company Bank Analyst Coverage Opinion chg cls Acorda Therapeutics Inc. (NASDAQ:ACOR) Baird Christopher Raymond Downgrade Neutral (from market outperform) -4% $26.34 Raymond also lowered his target to $31 from...
08:00 , Dec 20, 2010 |  BioCentury  |  Finance

Regulatory Milestones

Regulatory milestones Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) gained $2.72 (14%) to $22.79 last week after the European Medicines Agency's CHMP recommended approval of Xiapex collagenase clostridium histolyticum from Pfizer Inc. (NYSE:PFE) to treat Dupuytren's contracture in...
01:05 , Dec 16, 2010 |  BC Extra  |  Company News

Ramius, Royalty Pharma to acquire Cypress

Cypress Bioscience Inc. (NASDAQ:CYPB) agreed to a $6.50 per share cash offer by Ramius LLC and Royalty Pharma to acquire the 90.1% of the musculoskeletal and neurology company that Ramius does not already own. On...